Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ocrelizumab - Biogen/Genentech

Next Previous
Drug Profile

Ocrelizumab - Biogen/Genentech

Alternative Names: 2H7-monoclonal-antibody; 2nd Generation Anti-CD20; Anti-CD20 monoclonal antibody - Genentech; Humanised Anti-CD20 mAb; Monoclonal-antibody-2H7; OCR; OCRE; Ocrelizumab hyaluronidase ocsq - Roche; Ocrevus; Ocrevus SC; OCREVUS ZUNOVO; PRO 70769; R 1594; RG 1594; rhuMab 2H7; RO4964913

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec; Genentech
  • Developer Biogen; Biogen Idec; Chugai Pharmaceutical; Genentech; Roche
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Urologics
  • Mechanism of Action Antibody-dependent cell cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Discontinued Eye disorders; Haematological malignancies; Lupus nephritis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 24 Sep 2025 Adverse events and efficacy data from the phase-III ORATORIO-HAND trial in Multiple sclerosis released by Roche
  • 24 Sep 2025 Final efficacy data from the phase-III OCARINA II trial in Multiple sclerosis released by Roche
  • 06 Jun 2025 Roche completes the phase III OCARINA II trial in Multiple sclerosis in USA, Australia, Brazil, Canada, Turkey, France, Czech Republic, Italy, New Zealand, Poland and Spain (IV) (NCT05232825) (EudraCT2020-005448-48)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top